Journal of Diabetes Investigation最新文献

{"title":"Maturity-onset diabetes of the young: A proposal for updated nomenclature","authors":"Mustafa Tosur","doi":"10.1111/jdi.14320","DOIUrl":"10.1111/jdi.14320","url":null,"abstract":"<p>Given the contemporary understanding of diabetes genetics, the term “maturity-onset diabetes of the young (MODY)” warrants renaming. I propose adopting the term “monogenic diabetes” in conjunction with the specific gene name.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1818-1819"},"PeriodicalIF":3.1,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14320","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Association between variation in hemoglobin A1c levels and diabetes therapy-related quality of life in patients with diabetes”","authors":"","doi":"10.1111/jdi.14321","DOIUrl":"10.1111/jdi.14321","url":null,"abstract":"<p>Imai D, Ushigome E., Sakai R., Kitagawa N., Hamaguchi M., Yamazaki M., Fukui M. Association between variation in hemoglobin A1c levels and diabetes therapy-related quality of life in patients with diabetes. J Diabetes Investig. 2024 Aug;15:1042–1046.</p><p>In the Data collection paragraph of the Method, VIM (variability independent of mean) is corrected to be MAD (mean absolute deviation). In addition, the calculation results of ARV were incorrect. The contents of Tables 1 and 2 have been partially revised accordingly.</p><p>We apologize for this error.</p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 11","pages":"1702"},"PeriodicalIF":3.1,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14321","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on “Intra-islet α-cell Gs signaling promotes glucagon release”","authors":"Tadahiro Kitamura","doi":"10.1111/jdi.14317","DOIUrl":"10.1111/jdi.14317","url":null,"abstract":"<p>The Gs receptor in pancreatic α cells promotes glucagon transcription and secretion via increasing cAMP. The Gi receptor in pancreatic α cells suppresses glucagon secretion via decreasing cAMP. The Gq receptor in pancreatic α cells promotes glucagon secretion via releasing Ca⁺⁺ from ER to cytoplasm.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1727-1728"},"PeriodicalIF":3.1,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical challenges in early pregnancy in Japan: An update on gestational diabetes","authors":"Takashi Sugiyama,&nbsp;Maki Kawasaki,&nbsp;Naoko Arata","doi":"10.1111/jdi.14319","DOIUrl":"10.1111/jdi.14319","url":null,"abstract":"&lt;p&gt;The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; and subsequently follow-up studies&lt;span&gt;&lt;sup&gt;2-4&lt;/sup&gt;&lt;/span&gt; have reported that gestational diabetes mellitus (GDM) is associated with various adverse pregnancy outcomes, which increases the mother's susceptibility to developing type 2 diabetes, and the child's susceptibility to developing obesity and impaired glucose tolerance in the future&lt;span&gt;&lt;sup&gt;3-5&lt;/sup&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p&gt;GDM is diagnosed based on the presence of at least one of the following criteria: pre-load, 1- and 2-h values of the 75-g oral glucose tolerance test (75-g OGTT) of 92, 180 and 153 mg/dL, respectively, at 24–28 weeks' gestation&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt;. These cutoff values were established and recommended by the International Association of Diabetes and Pregnancy Study Groups (IADPSG)&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt;, based on the results of the HAPO study&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p&gt;The diagnostic criteria in Japan are the same as those of the IADPSG&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt;. Although Japan did not participate in the HAPO study, a separate Japanese epidemiological study showed that GDM diagnosed during the second half of pregnancy using these diagnostic criteria was associated with a significantly higher risk of premature birth (&lt;37 weeks), birthweight &gt;90th percentile, hypertensive disorders of pregnancy and cesarean section&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt;. These findings show that the perinatal prognosis of GDM in the second half of pregnancy, as defined by these diagnostic criteria, is poor among Japanese women. Furthermore, Japan uses similar diagnostic cutoff values as the GDM diagnostic criteria in the first half of pregnancy as in the second half of pregnancy. This policy has led to an increase in the incidence of GDM in Japan, as well as other countries&lt;span&gt;&lt;sup&gt;8, 9&lt;/sup&gt;&lt;/span&gt;. Incidentally, one study on the prognosis of GDM in the first half of pregnancy in Japan reported that women diagnosed with GDM during the first half of pregnancy had a higher incidence of pre-eclampsia and cesarean section&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt;. We also previously showed that a GDM diagnosis in early pregnancy was associated with adverse pregnancy outcomes compared with a GDM diagnosis in late pregnancy using a previous diagnostic criteria in Japan&lt;span&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/span&gt;. Indeed, it should also be noted that Australia, USA and the UK do not apply these criteria for GDM during early pregnancy so far.&lt;/p&gt;&lt;p&gt;An important point is that the HAPO study, which formed the basis of the diagnostic criteria for GDM, was based on the 75-g OGTT from 24 to 32 weeks of pregnancy, and not on the blood glucose levels identified during 75-g OGTT in the first half of pregnancy. Indeed, our research has shown that blood glucose levels during 75-g OGTT differ between early and late pregnancy&lt;span&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/span&gt;. As such, the diagnostic criteria for GDM during early pregnancy based on epidemiological and clinical s","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1729-1731"},"PeriodicalIF":3.1,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14319","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexistence of high visceral fat area and sarcopenia and atherosclerotic markers in older patients with diabetes: Is there an association?","authors":"Christian Saleh","doi":"10.1111/jdi.14322","DOIUrl":"10.1111/jdi.14322","url":null,"abstract":"&lt;p&gt;Dear Sir,&lt;/p&gt;&lt;p&gt;Sato &lt;i&gt;et al&lt;/i&gt;.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; published in the August issue a study titled “Coexistence of high visceral fat area and sarcopenia is associated with atherosclerotic markers in old-old patients with diabetes: A cross-sectional study”. The authors aimed to investigate whether there is an association between sarcopenic obesity and the progression of atherosclerotic lesions in older patients&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;. In their cross-section study, 118 participants were included, “50 (42.4%) were men and 68 (57.6%) were women, with a median age of 80 years, and 6 (5%) had type 1 diabetes. The median body mass index (BMI) was 24.0 kg/m&lt;sup&gt;2&lt;/sup&gt;, the median HbA1c level was 9.1%, and the median duration of diabetes mellitus was 18 years”&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;. As surrogate marker for preclinical atherosclerosis, the carotid intima-media thickness (cIMT) was used, measured by sonography&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;. The authors measured cIMT bilaterally at the common carotid artery (CCA&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;). The study showed that the cIMT “in the group showing sarcopenia with a high visceral fat area was significantly higher than that in the control group (&lt;i&gt;P&lt;/i&gt; = 0.012)”&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;. The authors concluded, “Although further research is needed to clarify whether sarcopenic obesity should be treated as a risk factor for atherosclerosis, this study suggests that evaluation of both sarcopenia and visceral fat mass is important in the evaluation of older patients with diabetes mellitus because they may serve as markers of atherosclerosis”&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;. Some comments are here needed to evaluate the cIMT results of this study in a more balanced way. The authors measured only in one segment of the carotid tree, namely the CCA&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;. A single location cIMT measurement is performed by some authors for technical reasons, namely a higher spatial resolution of the far wall of the CCA&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;. The disadvantage of a single-site CCA measurement however, given the asymmetric presentation of atherosclerosis, is that it may coincide with a normal segment but of an atherosclerotic affected vessel, providing an inaccurate cIMT measure.   Other authors perform therefore a multi-site cIMT data acquisition that considers several sections of the CA tree, for example, far/near walls of CCA, bifurcation, and/or internal CA&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;. Sato &lt;i&gt;et al&lt;/i&gt;.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; did not report further, if cIMT measurement was synchronized with the cardiac cycle (the end-diastolic phase). CIMT values differ during the cardiac cycle, due to changes in vessel diameter with reported mean differences of 0.041 mm&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;. In summary: If cIMT is used as surrogate marker for preclinical atherosclerosis importantly to mind that submillimetric differences are sufficient to categorize subjects into different cIMT groups. Authors need to have a meticulous measure","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1820"},"PeriodicalIF":3.1,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14322","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of glucokinase haploinsufficiency on the pancreatic β-cell mass and function of long-term high-fat, high-sucrose diet-fed mice","authors":"Ikumi Shigesawa,&nbsp;Akinobu Nakamura,&nbsp;Yuki Yamauchi,&nbsp;Shinichiro Kawata,&nbsp;Asuka Miyazaki,&nbsp;Hiroshi Nomoto,&nbsp;Hiraku Kameda,&nbsp;Yasuo Terauchi,&nbsp;Tatsuya Atsumi","doi":"10.1111/jdi.14307","DOIUrl":"10.1111/jdi.14307","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>We previously showed that glucokinase haploinsufficiency improves the glucose tolerance of <i>db/db</i> mice by preserving pancreatic β-cell mass and function. In the present study, we aimed to determine the effects of glucokinase haploinsufficiency on the β-cell mass and function of long-term high-fat, high-sucrose (HFHS) diet-fed mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Four-week-old male glucokinase haploinsufficient (<i>Gck</i>^<i>+/−</i>) mice and 4-week-old male wild-type (<i>Gck</i>^<i>+/+</i>) mice (controls) were each divided into two groups: an HFHS diet-fed group and a normal chow-fed group, and the four groups were followed until 16, 40 or 60 weeks-of-age. Their glucose tolerance, glucose-stimulated insulin secretion and β-cell mass were evaluated. In addition, islets were isolated from 40-week-old mice, and the expression of key genes was compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><i>Gck</i>^<i>+/−</i>HFHS mice had smaller compensatory increases in β-cell mass and glucose-stimulated insulin secretion than <i>Gck</i>^<i>+/+</i>HFHS mice, and their glucose tolerance deteriorated from 16 to 40 weeks-of-age. However, their β-cell mass and glucose-stimulated insulin secretion did not decrease between 40 and 60 weeks-of-age, but rather, tended to increase, and there was no progressive deterioration in glucose tolerance. The expression of <i>Aldh1a3</i> in pancreatic islets, which is high in several models of diabetes and is associated with an impairment in β-cell function, was high in <i>Gck</i>^<i>+/+</i>HFHS mice, but not in <i>Gck</i>^<i>+/−</i>HFHS mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Glucokinase haploinsufficiency prevents the progressive deterioration of pancreatic β-cell mass/function and glucose tolerance in long-term HFHS diet-fed mice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1732-1742"},"PeriodicalIF":3.1,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14307","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple positive points during the 75 g oral glucose tolerance test are good predictors for early insulin therapy in gestational diabetes mellitus diagnosed before 24 gestational weeks","authors":"Yoshifumi Kasuga,&nbsp;Marina Takahashi,&nbsp;Kaoru Kajikawa,&nbsp;Keisuke Akita,&nbsp;Junko Tamai,&nbsp;Yuka Fukuma,&nbsp;Yuya Tanaka,&nbsp;Keita Hasegawa,&nbsp;Toshimitsu Otani,&nbsp;Satoru Ikenoue,&nbsp;Mamoru Tanaka","doi":"10.1111/jdi.14318","DOIUrl":"10.1111/jdi.14318","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>This study evaluated the risk factors for insulin therapy before 24 gestational weeks (early insulin therapy) in pregnant women with gestational diabetes diagnosed before 24 gestational weeks (E-GDM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This study included 530 singleton mothers with E-GDM who underwent a 75 g oral glucose tolerance test (OGTT) in the first trimester at Keio University Hospital between January 2013 and December 2021. E-GDM can be classified according to its management into only diet therapy until delivery (Diet E-GDM), insulin therapy started before 24 gestational weeks (EarlyIns E-GDM), and insulin therapy started after 24 gestational weeks (LateIns E-GDM). We analyzed the risk factors for EarlyIns E-GDM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients with EarlyIns E-GDM had a significantly higher maternal age at delivery, pre-pregnancy BMI, first trimester hemoglobin A1c, 1 h plasma glucose levels (1 h-PG), and 2 h-PG, as well as a more pronounced initial increase and subsequent decrease, compared with those in the Diet E-GDM group. However, the Apgar scores at both 1 and 5 min were significantly lower in patients with EarlyIns E-GDM than in those with Diet E-GDM. The number of abnormal values in the OGTT showed the largest area under the receiver operating characteristic curve (AUC) for predicting EarlyIns E-GDM (0.83, 95% confidence interval [CI]: 0.79–0.86), followed by the 1 h-PG value (AUC: 0.81, 95% CI: 0.77–0.85). The initial increase showed the third largest AUC (0.78, 95% CI: 0.74–0.82).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although further research is needed, our data suggest the importance of early insulin therapy in cases of E-GDM with multiple abnormal OGTT values, especially with high 1 h-PG levels and initial increase.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1803-1808"},"PeriodicalIF":3.1,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14318","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP-STAR study","authors":"Hanako Nakajima,&nbsp;Hiroshi Okada,&nbsp;Akinori Kogure,&nbsp;Takafumi Osaka,&nbsp;Takeshi Tsutsumi,&nbsp;Masayoshi Onishi,&nbsp;Kazuteru Mitsuhashi,&nbsp;Noriyuki Kitagawa,&nbsp;Shinichi Mogami,&nbsp;Akane Kitamura,&nbsp;Michiyo Ishii,&nbsp;Naoto Nakamura,&nbsp;Akio Kishi,&nbsp;Sato Eiko,&nbsp;Masahide Hamaguchi,&nbsp;Michiaki Fukui","doi":"10.1111/jdi.14314","DOIUrl":"10.1111/jdi.14314","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Nocturia impairs the quality of life in patients with type 2 diabetes mellitus. Although sodium glucose co-transporter 2 inhibitors (SGLT2i) such as tofogliflozin increase urine volume, their impact on nocturia, in conjunction with dietary salt restriction, is less clear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This multicenter, open-label, randomized, parallel-group trial included 80 subjects with type 2 diabetes and nocturia. The patients were divided into two groups: one receiving tofogliflozin, the shortest half-life, without salt restriction, and the other receiving both tofogliflozin and dietary salt restriction. The primary endpoint was nocturia frequency at 12 weeks. The secondary outcomes included changes in daytime urination frequency, urine volume, and home blood pressure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At 12 weeks, there were no significant differences in nocturia changes between both groups. Nocturia frequency did not change in the tofogliflozin without salt restriction group from 1.5 ± 0.8 to 1.3 ± 1.1 times per night (<i>P</i> = 0.297), and significantly decreased from 1.6 ± 1.0 to 1.3 ± 0.7 times per night in the tofogliflozin and dietary salt restriction group (<i>P</i> = 0.049). There was a trend toward increased urine volume and frequency during the daytime in the group with salt restriction, indicating a time-shift effect of the short half-life tofogliflozin and salt restriction on urinary time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The frequency of nocturia after tofogliflozin did not increase. Tofogliflozin reduced nocturia when combined with salt restriction. Furthermore, daytime urine volume and frequency showed an increasing trend, suggesting a shift in urine production to daytime hours due to the short half-life of tofogliflozin. Dietary modifications can enhance the therapeutic benefits of tofogliflozin in managing nocturia in people with type 2 diabetes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1809-1817"},"PeriodicalIF":3.1,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14314","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Problems in screening for gestational diabetes mellitus by measurement of casual blood glucose levels at 24–28 gestational weeks","authors":"Masako Tomimoto,&nbsp;Kenji Tanimura,&nbsp;Naohisa Masuko,&nbsp;Akiko Uchida,&nbsp;Hitomi Imafuku,&nbsp;Masashi Deguchi,&nbsp;Akane Yamamoto,&nbsp;Yushi Hirota,&nbsp;Wataru Ogawa,&nbsp;Yoshito Terai","doi":"10.1111/jdi.14310","DOIUrl":"10.1111/jdi.14310","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>This study aimed to evaluate the problems in screening for gestational diabetes mellitus (GDM) by casual blood glucose (CBG) measurements at 24–28 gestational weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Overall, 763 pregnant women who underwent the 50-g glucose challenge test (GCT) at 24–28 gestational weeks were enrolled. The preload blood glucose (0-h BG) level of 50-g GCT was considered as CBG.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 240 women with BG levels at 1-h after loading (1-h BG) on 50-g GCT ≥140 mg/dL underwent the 75-g oral glucose tolerance test, and 98 (40.8%) were diagnosed with GDM. Of the 99 women with GDM, 71 (71.7%) had 0-h BG on 50-g GCT &lt;100 mg/dL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study, where pregnant women underwent both CBG and 50-g GCT simultaneously, showed that when CBG at 24–28 gestational weeks ≥100 mg/dL alone was used for screening GDM, many pregnant women with GDM were overlooked.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1797-1802"},"PeriodicalIF":3.1,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14310","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142248194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic dysfunction-associated steatotic liver disease: A superior predictor for incident type 2 diabetes over traditional criteria – NAGALA study","authors":"Kimiko Sakai,&nbsp;Takuro Okamura,&nbsp;Ema Toyokuni,&nbsp;Hiroshi Okada,&nbsp;Akihiro Obora,&nbsp;Takao Kojima,&nbsp;Masahide Hamaguchi,&nbsp;Michiaki Fukui","doi":"10.1111/jdi.14315","DOIUrl":"10.1111/jdi.14315","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>The 2023 Delphi consensus recommended the use of new term, metabolic dysfunction-associated steatotic liver disease (MASLD), aiming conceptual shift from the conventional non-alcoholic fatty liver disease (NAFLD). The association between NAFLD and type 2 diabetes mellitus (T2DM) development is well known. This study aimed to examine the correlation between MASLD and T2DM development, comparing their utility as predictors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This retrospective cohort study obtained data from a medical health checkup program conducted at Asahi University Hospital, Japan, between 2004 and 2021. Logistic regression analysis was used to assess the association between MASLD and incident T2DM over 5 years. To compare the predictive utility of NAFLD and MASLD, receiver operating characteristic curves were drawn, followed by area under the curve (AUC) comparisons.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 15,039 participants (59.6% males; median [interquartile range {IQR}] age, 44 [38, 50] years) were included. Out of 2,682 participants meeting the criteria for MASLD, 234 individuals (8.7%) developed T2DM. Multivariate analysis revealed a significantly elevated risk of T2DM in MASLD compared with the reference healthy group (without steatotic liver disease or cardiometabolic risk), presenting an OR of 127.00 (95% CI 40.40–399.00, <i>P</i> &lt; 0.001). The concordance rate of diagnosis between NAFLD and MASLD was 98.7%. The AUC values were 0.799 for NAFLD and 0.807 for MASLD, respectively. Comparative analysis of the AUC showed a statistical difference between NAFLD and MASLD (<i>P</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>MASLD was shown to be a significant risk factor for incident T2DM, exhibiting a potentially higher predictive capacity than conventional NAFLD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"15 12","pages":"1788-1796"},"PeriodicalIF":3.1,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14315","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142277669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}